C123P: Imdevimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Catalog No.: C123P | **Product Name:** Imdevimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

The research grade Imdevimab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C123P
Product Name	Imdevimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Imdevimab; REGN10987; anti-SARS-CoV-2 Spike; COVID-19 antibody
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1.
Source/Host	The anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade imdevimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by imdevimab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Imdevimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Imdevimab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is imdevimab biosimilar research grade? Imdevimab (also known as REGN10987) is a recombinant human monoclonal antibody that targets the spike protein of SARS-CoV-2. It was developed as part of the antibody cocktail REGN-COV2 (casirivimab and imdevimab) for the treatment and prevention of COVID-19. Imdevimab binds to a distinct epitope on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, blocking viral attachment to the ACE2 receptor and neutralizing the virus. Imdevimab biosimilar uses the same protein sequences as the therapeutic antibody imdevimab.